Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

• Solène M. Evrard,
• Sarah Péricart,
• David Grand,
• Nadia Amara,
• Frédéric Escudié,
• Julia Gilhodes,
• Pierre Bories,
• Alexandra Traverse-Glehen,
• Romain Dubois,
• Pierre Brousset,
• Marie Parrens,
• Camille Laurent

Affiliations

Solène M. Evrard

Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole;Toulouse III Paul Sabatier University;Inserm, UMR1037 Centre de Recherche en Cancerologie de Toulouse, laboratoire d’excellence TOUCAN

Sarah Péricart

Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole

David Grand

Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole

Nadia Amara

Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole

Frédéric Escudié

Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole

Julia Gilhodes

Department of Biostatistics, IUCT-Oncopole, CHU Toulouse

Pierre Bories

Regional Cancer Network Onco-occitanie, IUCT-Oncopole, Toulouse

Alexandra Traverse-Glehen

Hospices Civils de Lyon, Claude Bernard Lyon 1 University, INSERM 1052, Pierre-Bénite

Romain Dubois

Institut de Pathologie, CHU Lille, Avenue Oscar Lambret

Pierre Brousset

Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole;Toulouse III Paul Sabatier University;Inserm, UMR1037 Centre de Recherche en Cancerologie de Toulouse, laboratoire d’excellence TOUCAN

Marie Parrens

Pathology, CHU Bordeaux, Inserm U1053, France

Camille Laurent

Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole;Toulouse III Paul Sabatier University;Inserm, UMR1037 Centre de Recherche en Cancerologie de Toulouse, laboratoire d’excellence TOUCAN